Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	10.46B 68.32B 9.14B 8.43B 7.77B 14.65B 1,007B 14.97B 101B 39.64B 493B 39.27B 38.41B 1,698B	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	10.49B 68.51B 9.16B 8.46B 7.79B 14.69B 1,010B 15.02B 101B 39.75B 495B 39.38B 38.51B 1,702B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

30/05/24	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
28/06/22	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
26/04/21	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
17/02/20	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
07/02/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
30/01/20	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
14/01/20	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
25/11/19	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
25/11/19	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
13/11/19	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
12/11/19	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
31/10/19	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

02/06/21	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
17/02/20	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
29/01/20	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
27/01/20	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Stock

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news : Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	13/09/2017
Stacy Wheeler COO	Chief Operating Officer	-	01/03/2016

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
MERCK & CO., INC.	-0.10%	+3.21%	+59.45%	+20.34%	315B
MERCK KGAA	-1.20%	-2.43%	+23.24%	-8.55%	67.81B
HALOZYME THERAPEUTICS, INC.	+0.35%	+2.11%	+37.84%	+85.31%	9.23B
KYOWA KIRIN CO., LTD.	+0.34%	+0.51%	+5.21%	-1.87%	8.56B
SK BIOPHARMACEUTICALS CO., LTD.	+1.53%	-3.64%	-22.91%	-2.70%	4.18B
BETTA PHARMACEUTICALS CO., LTD.	-11.03%	-12.07%	-8.02%	+16.19%	3.59B
YUHAN CORPORATION	+1.87%	+3.36%	-46.36%	+23.90%	3.55B
SUPERNUS PHARMACEUTICALS, INC.	-0.35%	-0.87%	+48.55%	+58.44%	2.79B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-7.41%	-2.37%	+3.91%	-24.38%	2.09B
Average	-1.60%	-1.08%	+11.21%	+18.52%	41.83B
Weighted average by Cap.	-0.36%	+1.96%	+49.31%	+16.41%

	2017	2018
Net sales	30.17M 197M 26.36M 24.33M 22.42M 42.26M 2.91B 43.2M 291M 114M 1.42B 113M 111M 4.9B	39.49M 258M 34.51M 31.85M 29.36M 55.33M 3.8B 56.56M 381M 150M 1.86B 148M 145M 6.41B
Net income	-9.54M -62.35M -8.34M -7.69M -7.09M -13.37M -919M -13.67M -91.97M -36.17M -450M -35.83M -35.05M -1.55B	-5.28M -34.53M -4.62M -4.26M -3.93M -7.4M -509M -7.57M -50.94M -20.04M -249M -19.85M -19.41M -858M
Net Debt	18.05M 118M 15.78M 14.56M 13.42M 25.29M 1.74B 25.85M 174M 68.44M 851M 67.79M 66.31M 2.93B	29.38M 192M 25.68M 23.7M 21.84M 41.17M 2.83B 42.08M 283M 111M 1.39B 110M 108M 4.77B